Phase III trials in relapsed and/or refractory MM: efficacy
| Study (reference) . | Regimens . | Patients, n . | Prior therapies, median, n (range) . | Experimental vs placebo arm . | ||
|---|---|---|---|---|---|---|
| ORR, % . | ≥VGPR, % . | PFS, mo (HR) . | ||||
| Lenalidomide-based regimens | ||||||
| ASPIRE (25) | Rd ± carfilzomib | 792 | 2 (1-3) | 87 vs 67 | 70 vs 40 | 26 vs 18 (0.69) |
| TOURMALINE-MM1 (28) | Rd ± ixazomib | 722 | 1 (1-3) | 78 vs 72 | 48 vs 39 | 20.6 vs 14.7 (0.74) |
| ELOQUENT 2 (27) | Rd ± elotuzumab | 646 | 2 (1-3) | 79 vs 66 | 33 vs 28 | 19.4 vs 14.9 (0.70) |
| POLLUX (29) | Rd ± daratumumab | 569 | 1 (1-11) | 93 vs 76 | 76 vs 44 | Not reached vs 18.4 (0.37) |
| Bortezomib-based regimens | ||||||
| PANORAMA 1 (34) | Vd ± panobinostat | 768 | 1 (1-3) | 61 vs 55 | Not mentioned | 12 vs 8 (0.63) |
| CASTOR (33) | Vd ± daratumumab | 498 | 2 (1->3) | 83 vs 63 | 59 vs 29 | Not reached vs 7.16 (0.39) |
| Randomized phase II study (35) | Vd ± elotuzumab | 150 | 1 (1-3) | 66 vs 63 | 37 vs 27 | 9.7 vs 6.9 (0.72) |
| ENDEAVOR (31) | Kd vs Vd | 929 | 1 (1-3) | 77 vs 63 | 54 vs 29 | 18.7 vs 9.4 (0.53) |
| Study (reference) . | Regimens . | Patients, n . | Prior therapies, median, n (range) . | Experimental vs placebo arm . | ||
|---|---|---|---|---|---|---|
| ORR, % . | ≥VGPR, % . | PFS, mo (HR) . | ||||
| Lenalidomide-based regimens | ||||||
| ASPIRE (25) | Rd ± carfilzomib | 792 | 2 (1-3) | 87 vs 67 | 70 vs 40 | 26 vs 18 (0.69) |
| TOURMALINE-MM1 (28) | Rd ± ixazomib | 722 | 1 (1-3) | 78 vs 72 | 48 vs 39 | 20.6 vs 14.7 (0.74) |
| ELOQUENT 2 (27) | Rd ± elotuzumab | 646 | 2 (1-3) | 79 vs 66 | 33 vs 28 | 19.4 vs 14.9 (0.70) |
| POLLUX (29) | Rd ± daratumumab | 569 | 1 (1-11) | 93 vs 76 | 76 vs 44 | Not reached vs 18.4 (0.37) |
| Bortezomib-based regimens | ||||||
| PANORAMA 1 (34) | Vd ± panobinostat | 768 | 1 (1-3) | 61 vs 55 | Not mentioned | 12 vs 8 (0.63) |
| CASTOR (33) | Vd ± daratumumab | 498 | 2 (1->3) | 83 vs 63 | 59 vs 29 | Not reached vs 7.16 (0.39) |
| Randomized phase II study (35) | Vd ± elotuzumab | 150 | 1 (1-3) | 66 vs 63 | 37 vs 27 | 9.7 vs 6.9 (0.72) |
| ENDEAVOR (31) | Kd vs Vd | 929 | 1 (1-3) | 77 vs 63 | 54 vs 29 | 18.7 vs 9.4 (0.53) |
ORR, overall response rate.